Strides Shasun Ltd on Friday announced an organizational restructuring plan which will see it demerge and list its active pharmaceutical ingredients (API) business, exit probiotics and cap its investment in the biotech business.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
